07:00 , Apr 29, 2013 |  BC Week In Review  |  Company News

BioCrea, Dresden University of Technology deal

BioCrea and the university will develop a human neuron screening platform for the discovery of treatments for neurodegenerative diseases, such as amyotrophic lateral sclerosis. The partners will jointly develop multiple induced pluripotent stem cell (iPSC)...
08:00 , Mar 5, 2012 |  BC Week In Review  |  Company News

biocrea, Boehringer Ingelheim deal

Boehringer acquired biocrea's phosphodiesterase-2 (PDE-2) program. The program's lead compound is BCA909 , a PDE-2 inhibitor in preclinical testing for mild cognitive impairment and Alzheimer's disease (AD). biocrea will receive an undisclosed cash payment from...
07:00 , Sep 19, 2011 |  BC Week In Review  |  Clinical News

biocrea preclinical data

In rats, BCR909 significantly reversed impaired novel object recognition that resulted from either disruption of cholinergic or glutamatergic neurotransmission. Furthermore, the phosphodiesterase-2 (PDE-2) inhibitor did not induce tolerance. Data were presented at the European College...
08:00 , Jan 3, 2011 |  BC Week In Review  |  Company News

biocrea management update

biocrea GmbH , Radebeul, Germany   Business: Neurology   Hired: Martin Gunthorpe as CSO, formerly head of electrophysiology and project leader in the Neurosciences Centre of Excellence for Drug Discovery at GlaxoSmithKline plc ; Viktor...
08:00 , Jan 3, 2011 |  BC Week In Review  |  Company News

Biotie autoimmune, pulmonary news

Biotie restructured and reduced headcount by 59 (73%) to 22 as part of its previously announced plans to discontinue its early-stage discovery efforts in order to focus on the clinical development of ronomilast and BTT-1023...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Company News

Biotie neurology news

Biotie spun out newco biocrea GmbH (Radebeul, Germany) to focus on developing phosphodiesterase (PDE) inhibitors to treat CNS disorders. Biotie granted biocrea rights to three PDE inhibitors which are planned to reach the clinic by...
07:00 , Nov 1, 2010 |  BC Week In Review  |  Company News

Biotie autoimmune, pulmonary news

Biotie said it will restructure and reduce headcount by 59 (73%) to about 22 as part of its plans to discontinue its early-stage discovery efforts in order to focus on the clinical development of ronomilast...
00:55 , Oct 30, 2010 |  BC Extra  |  Company News

Biotie planning restructuring, spinout

Biotie Therapies Corp. (HSE:BTH1V) will restructure and reduce headcount by 59 (73%) to about 22 as part of its plans to discontinue its early stage discovery efforts to focus on the clinical development of ronomilast...